StockVS

InMode Ltd. (INMD) Aandelenanalyse

Gezondheidszorg

InMode Ltd.

$13.81

+$0.07 (+0.51%)

Laatst bijgewerkt: 26 mei 2026

Koersverloop

Analyse

Bedrijfsoverzicht

InMode Ltd. is a prominent player in the healthcare sector, specifically operating within the medical devices industry where it focuses on advancing patient outcomes through specialized technology. The company's core business involves the design, development, manufacturing, and marketing of minimally invasive aesthetic medical products that utilize proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies. These products are distributed across key global markets including the United States, Europe, and Asia, serving a diverse international client base. With a market capitalization of $857.24M and annual revenue reaching $370.50M, the company demonstrates a significant operational footprint supported by an employee base of 660 professionals. These financial figures indicate that InMode holds a substantial position within its niche, commanding a valuation that reflects its established presence in the aesthetic medical device landscape.

Financiële gezondheid

InMode Ltd. reported a trailing twelve-month revenue of $370.50M, generating net income of $93.83M and an EBITDA of $86.08M during the same period. The substantial gap between the revenue figure and the net income reveals a robust cost structure where operating expenses and taxes consume a portion of the top line, leaving a healthy profit margin. The company generated free cash flow of $39.10M, which signifies strong financial flexibility allowing for potential capital expenditures, strategic acquisitions, or reinvestment in research and development without external financing. Profitability is further evidenced by a gross margin of 78.5%, an operating margin of 25.0%, and a profit margin of 25.3%, indicating high efficiency in production and pricing power relative to cost of goods sold. The balance sheet presents a conservative profile with cash reserves of $555.33M significantly outweighing total debt of $8.23M, supported by a debt-to-equity ratio of 1.20. This liquidity position is reinforced by a current ratio of 9.88, which suggests an exceptionally strong ability to meet short-term obligations with available assets. Furthermore, the return on equity stands at 13.5% while the return on assets is 6.9%, metrics that collectively highlight effective management in generating returns relative to shareholders' equity and the total asset base employed.

Waarderingsbeoordeling

Valuation metrics for InMode Ltd. include a trailing P/E ratio of 9.46 and a forward P/E of 8.84, suggesting that the market expects earnings to grow in the future as the forward multiple is lower than the trailing multiple. The price-to-book ratio is 1.25, which indicates that the company trades at a slight premium over its book value, reflecting intangible assets or growth prospects not fully captured on the balance sheet. Alternative valuation measures such as the price-to-sales ratio of 2.31 and an EV/EBITDA of 3.60 provide context on how the market prices revenue and earnings relative to enterprise value. The stock has a 52-week high of $16.74 and a 52-week low of $12.72, and depending on the current share price, the trading position relative to this range can be calculated to determine proximity to recent highs or lows. The beta of 2.12 indicates that the stock's price volatility is more than double that of the broader market, meaning price movements are expected to be amplified compared to the general index.

Growth & Income

InMode Ltd. experienced a revenue growth rate of 6.1% year over year, whereas earnings growth contracted by 63.5% year over year, implying that earnings are currently growing slower than revenue, likely due to one-time costs or non-recurring items affecting the bottom line. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the company retains all earnings rather than distributing them to shareholders. This retention strategy allows the firm to reinvest capital directly into growth initiatives, such as expanding its product portfolio or enhancing manufacturing capabilities, rather than paying out income. The overall growth and income profile is characterized by positive top-line expansion coupled with a lack of dividend income, focusing shareholder returns on potential capital appreciation and future operational scalability.

Vergelijking met sectorgenoten

InMode Ltd. (INMD) is actief in de Medische Apparatuur-sector. Zo verhoudt het zich tot de naaste sectorgenoten op basis van marktkapitalisatie:

Bedrijf Ticker Marktkapitalisatie K/W-verhouding
InMode Ltd. INMD $839.77M 10.2
Abbott Laboratories ABT $150.96B 24.3
Stryker Corporation SYK $119.99B 36.2
Medtronic plc MDT $99.63B 21.7

De gemiddelde K/W-verhouding in de Medische Apparatuur-sector is 60.2x. InMode Ltd. wordt verhandeld tegen een K/W van 10.2.

Deze analyse is gegenereerd door AI en dient alleen ter informatie. Het vormt geen financieel advies. Gegevens kunnen vertraagd of onnauwkeurig zijn. Doe altijd je eigen onderzoek en raadpleeg een gekwalificeerde financieel adviseur voordat je beleggingsbeslissingen neemt.

Over InMode Ltd.

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. The company also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. In addition, it offers hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company sells and markets its products in the United States, Canada, the United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxemburg, Italy, Germany, Austria, Japan, Australia, and India through distributors. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. The company was incorporated in 2008 and is headquartered in Yokne'am, Israel.

Bedrijfsbeschrijving wordt in het Engels weergegeven.

Bezoek website →

Belangrijke Cijfers

Marktkapitalisatie
$839.77M
K/W-verhouding
10.23
52-weken hoog
$16.74
52-weken laag
$12.72
Gem. Volume
925.50K
Bèta
1.98

Gegevens verstrekt door Yahoo Finance via yfinance. Dagelijks bijgewerkt.

Bedrijfsinfo

Beurs
NASDAQ
Land
Israel
Werknemers
660